Ceramide, a central hub in sphingolipid metabolism, serves as a critical bioactive signalling mediator that integrates lipid metabolism with multiple signalling pathways, primarily promoting autophagy and apoptosis. It influences female …
Elagolix and Myfembree are gonadotropin-releasing hormone (GnRH)-pathway therapies used for endometriosis, but their post-marketing safety reporting patterns remain incompletely characterized. Because spontaneous reporting databases are susceptible to reporting bias and …
Goserelin is a gonadotropin-releasing hormone (GnRH) agonist with a long history of clinical application and well-established efficacy and safety profile. Its mechanism of action centers on sustained GnRH receptor desensitization, …
Advanced maternal age (AMA) is a major challenge in reproductive medicine, compounded by coexisting conditions such as adenomyosis and endometriosis, which impair oocyte competence and endometrial receptivity. Prolonged gonadotropin-releasing hormone …
To investigate the efficacy of different pretreatment protocols for women with endometriosis undergoing IVF. We systematically searched the Cochrane Library, PubMed, Medline, and Embase from inception to April 30, 2025, …
This narrative review explores contemporary therapeutic options and critically assesses surgical results and in vitro fertilization-intracytoplasmic sperm injection (IVF/ICSI) outcomes in women affected by endometriosis, deep infiltrating endometriosis (DIE) and/or …
This exploratory pilot study aimed to assess the preliminary clinical effects of leuprorelin acetate microspheres for injection [gonadotropin-releasing hormone agonist (GnRH-a)] combined with levonorgestrel-releasing intrauterine system (LNG-IUS) in treating endometriosis …
To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.
Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …
Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of …